Entity > Corporation > US > New York City New York > Inhibrx

About Inhibrx

Inhibrx, Inc. is a clinical-stage biotechnology company dedicated to helping people with life-threatening diseases through scientific innovation and excellence. Inhibrx, Inc. employs various protein engineering methods to address the specific needs of complex targets and diseases, including its proprietary sdAb platform.

The Proprietary Sdab Platform From Inhibrx, Inc: Our proprietary sdAb platform enables us to address complex target biology where other biological approaches have failed or are suboptimal. Our precision engineering enables the generation of therapeutic candidates with defined valences and specificities that we believe can lead to optimal mechanisms of action.

Currently, Four Inhibrx, Inc. Programs Are In Ongoing Clinical Trials: Drawing on the breadth and depth of our team's experience and capabilities, and using our proprietary technology, we have developed a promising pipeline that we believe has properties and mechanisms of action superior to existing approaches in the field. Three programs target the treatment of various cancers and one targets alpha-1 antitrypsin deficiency (AATD). In addition, INBRX-121 is our newest preclinical program currently in cell line development.

Inhibrx, Inc. And Bluebird Bio Began A Research Collaboration In 2016: Since then, the collaboration has focused on the discovery, development and commercialization of chimeric antigen receptor (CAR) T-cell therapies using Inhibrx's proprietary single-domain antibody (sdAb) platform for multiple cancer targets.

The Formation And Headquarters Of Inhibrx, Inc: Inhibrx was founded in 2010 and is currently headquartered in La Jolla, California, USA.

The Mission Of Inhibrx, Inc. Is To Provide Optimized Biologic Therapeutics To People With Life-Threatening Diseases: To achieve this goal, we have built a large and diverse pipeline that has the potential to impact cancer and rare diseases through our single-domain antibody platform technology. Single-domain antibodies (sdAbs) provide a small, simple, modular target binding domain that can be combined in multiple ways to meet the specific needs of unique biological targets.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Inhibrx

Company Attribute Value
Address StreetAddress: 11025 N Torrey Pines Rd Ste 200, AddressLocality: La Jolla, AddressRegion: California, PostalCode: 92037, AddressCountry: United States
Founding Date 2011
Name Inhibrx
Number Of Employees 106
Revenue $7,271,000 USD
Ticker Symbol NASDAQ: INBX
Url inhibrx
Linkedin linkedin
Google google
Wikidata wikidata



New York City, US
23 Jun 2024

New York City, US
23 Jun 2024


Page: 1 Desktop | Laptop Devices
Inhibrx | Discover our clinical-stage biotechnology company.
We're a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and excellence. Anchored ... › media-room › press-releases
Press Release: Sanofi to acquire Inhibrx, Inc., adding ...
Jan 23, 2024 — Sanofi will acquire all outstanding shares of Inhibrx for $30.0 per share in cash, representing an equity value of approximately $1.7 billion ( ... › news-releases › inhibrx-a...
Inhibrx Announces Sale of INBRX-101 to Sanofi for an ...
Jan 23, 2024 — Sanofi's acquisition of Inhibrx is subject to the completion of the New Inhibrx spin-off transaction and other customary closing conditions, ... › news-releases › inhibrx-i...
Inhibrx, Inc. Announces Updated When-Issued Trading ...
May 10, 2024 — The record date for the Spin-Off remains May 17, 2024 and the Company continues to expect that the distribution of shares of SpinCo common stock ... › Archives › edgar › data › inhibr...
Under this agreement, the Company is entitled to receive specified development milestone payments of up to an aggregate of $ 51.5 million per therapeutic, as ... › 2020-08-21-Inhibrx...
Inhibrx Announces Closing of Initial Public Offering ... - Investors
Registration statements relating to these securities became effective on August 18, 2020. This offering was made only by means of a prospectus. › quote › INBX
Inhibrx Biosciences, Inc. (INBX) Stock Price, News, Quote & ...
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening ...
Related Searches
Related Searches
Inhibrx Sanofi
Inhibrx news
Inhibrx IPO
Google My Business
Google My Business

Inhibrx (Biotechnology company in San Diego, California)
  • Located in : Torrey Pines Science Park
  • Address : 11025 N Torrey Pines Rd STE 200, La Jolla, CA 92037
  • Phone : (858) 795-4220

Related Entities Inhibrx

Entity Home Kalicube Pro Entity Page
Inhibrx Entity Home Inhibrx on Kalicube

All information on this page is taken from publicly available sources, and the analysis we provide is a representation of Google's search results for the entity and does not represent any opinion or judgement about the entity by Kalicube itself. If you disagree with this analysis, please contact us and cite this reference : 193787